MDxHealth SA today moved ahead to announce its signing into a five-year agreement with EXACT Sciences Corporation (NASDAQ:EXAS).The new agreement will see the two engage in a close collaboration of course in the growing field of molecular diagnostics and epigenetics.
This will indeed be the building of a long-standing relationship that spans about a decade. The new agreement will see Exact Sciences and MDxHealth get to share the proprietary technologies arising from their respective ground-breaking discovery as well as in carrying out some major developments in the fields of molecular diagnostics and epigenetics.
According to some of the top company analysts, the collaboration may result in the two parties moving ahead to identify opportunities to share technologies in a wide range of indications, including lung cancers and urologic.
Contemporaneously with the execution of the collaboration agreement, it has been revealed that the provider is exacting plans to acquire the MDxHealth patents targeting colorectal cancer, including the sort of technology that covers the use of FIT (fecal immunochemical test) in combination with methylation and its DNA methylation biomarker, NDRG4 in a major combination with methylation. The new acquisitions include the one-time fees amounting to about $15 million, including payments thought to have been accrued since July 2016.
The CSO of MDxHealth, Prof. Dr. Wim van Criekinge in a statement said, “With its ground-breaking achievements in molecular diagnostics, Exact Sciences is an ideal partner for us to collaborate with in the identification and development of new biomarkers for clinical diagnostic products. The collaboration may allow each party to better capitalize on its cutting-edge epigenetic research and development efforts to bring new products and services to market to improve patient lives.”
One thing that is for sure is that MDxHealth has moved quite long way towards pouting itself up as an industry leader and will continue to do more along that line. CSO and SVP of R&D of Exact Sciences, Dr. Graham Lidgard in making his statement said, “MDxHealth has established itself as a leader in the discovery and development of epigenetic and molecular diagnostics technologies, particularly in the field of urology. We are delighted to continue our long-standing scientific co-operation through this new agreement, which has the potential to benefit both companies` product development programs.”
The future seems bright for the top provider, but operating with reality is something that we will just have to wait and see.
